Protect

搜索文档
Fortrea Holdings Inc. Class Action: The Gross Law Firm Reminds Fortrea Holdings Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 1, 2025 – FTRE
GlobeNewswire News Room· 2025-06-18 21:22
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of FTRE during the timeframe list ...
CISO Global Expands CHECKLIGHT Offering with Tailored Packages for PEO Firms and Financial Management Companies
Globenewswire· 2025-06-18 20:30
Scottsdale, AZ, June 18, 2025 (GLOBE NEWSWIRE) -- CISO Global (NASDAQ: CISO), a leader in AI- powered cybersecurity software and compliance services, announced today the launch of specialized CHECKLIGHT packages tailored specifically for Professional Employer Organizations (PEOs) and Financial Management companies. This initiative democratizes access to CISO Global's state-of-the-art cybersecurity technology and its globally underwritten financial protection coverage, creating a robust security framework ac ...
Qualys Solutions Recognized for Exceptional Performance at SC Awards Europe 2025; Wins in Two Categories
Prnewswire· 2025-06-17 21:00
Qualys TotalCloud wins Best Cloud Security Solution; Qualys VMDR awarded Best Vulnerability Management Solution for third consecutive year FOSTER CITY, Calif., June 17, 2025 /PRNewswire/ -- Qualys, Inc. (NASDAQ: QLYS), a leading provider of disruptive cloud-based IT, security, and compliance solutions, announced wins in two categories at the 2025 SC Awards Europe. Qualys TotalCloud received the top accolade in the Best Cloud Security Solution category, and for the third consecutive year, Qualys Vulnerabilit ...
Ming Dynasty Culture Forum 2025 Opens, Exploring New Paths for the Inheritance and Innovation of Ming Culture
Globenewswire· 2025-06-17 18:13
文章核心观点 2025年6月14日“印象明朝:世界遗产篇章”——2025明朝文化论坛开幕,旨在探索和弘扬明朝文化,昌平区连续四年举办该论坛成果丰硕,未来将继续深化明朝文化研究与传承 [1][2][5] 论坛概况 - 论坛由开幕式、四个分论坛和文物展览组成,五个明皇陵首次合作,聚焦科技赋能文化遗产,推动北京文化中心建设和文化交流互鉴 [2] 开幕式嘉宾发言 - 中国明史学会会长高寿仙作“文明交流互鉴语境下的明文化”主题演讲,探讨明朝跨文化交流成就 [3] - 故宫博物院学术委员会主任单霁翔作“让明文化遗产活起来”演讲,以昌平定陵VR体验馆为例说明数字技术活化文物方法 [3] - 中国人民大学教授毛佩琦作“明朝对中华民族共同体发展的杰出贡献”演讲,阐述明朝制度设计等方面成就 [3] - 中医大师王琦作“从《本草纲目》看中医药的传承与发展”演讲,分析明朝医学繁荣及遗产 [3] 文物展览 - 论坛配套“印象明朝:世界遗产篇章”明朝文物主题展在全球明文化交流中心同期举行,展出超百件明朝珍贵文物 [4] 历届论坛成果 文化遗产保护 - 昌平区获批《明十三陵保护总体规划》,实施主神道重新开放等举措,制定考古工作计划,推进市级文物保护利用示范区建设,重塑明十三陵遗址空间布局 [6] 学术研究 - 组建120位学者智库,出版《2022明文化论坛成果汇编》等多部出版物,与多所高校和机构建立合作研究框架 [7] 文旅融合 - 制定明十三陵全域开放综合方案,2030年实现主要陵墓全面开放,围绕遗址开发83平方公里文旅区,深化“明文化+”融合模式,举办11场明朝文物主题展和13场展览活动,“邂逅万历”VR展成文化遗产数字化活化典范 [8][9][10] 未来展望 - 昌平区将基于2025年论坛成果,深化明朝文化研究、阐释和活化,推动非遗活态传承,加速文旅融合项目实施,探索明文化资源,目标成为全球明文化研究交流中心,助力北京文化中心建设和中华文化传承 [12]
2025年电子消费品趋势预测分析
搜狐财经· 2025-06-17 17:27
随着科技的飞速发展,电子消费品市场也在不断地演变。到了2025年,我们可以预见到一些显著的趋势,这些趋势将深刻影响 着我们的日常生活和消费习惯。 环境可持续性也是2025年电子消费品的一个重要趋势。随着全球对环境保护意识的增强,消费者越来越倾向于选择那些对环境 影响较小的产品。因此,电子消费品制造商将需要开发更加节能和可回收的产品,以满足市场需求。 隐私保护也是电子消费品领域不可忽视的问题。随着越来越多的个人数据被收集和分析,消费者对隐私保护的需求也在不断增 加。因此,电子消费品制造商需要在设计产品时考虑到数据安全和隐私保护,以赢得消费者的信任。 可穿戴设备也将在2025年迎来新的发展。随着健康意识的提高,人们越来越关注个人健康数据的追踪和管理。因此,智能手表 和健康追踪器将变得更加普及,它们不仅能够监测心率和睡眠质量,还能够提供更深入的健康分析和建议。 虚拟现实(VR)和增强现实(AR)技术也将成为电子消费品市场的热点。这些技术将不再局限于游戏和娱乐领域,而是扩展 到教育、医疗和零售等多个行业。通过VR和AR,用户可以获得更加沉浸式的体验,无论是学习新技能还是进行远程购物。 总的来说,2025年的电子消费品 ...
Publication of transparency notification
Globenewswire· 2025-06-17 00:00
Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated marketGhent, BELGIUM, June 16, 2025 (GLOBE NEWSWIRE) -- Press release - regulated information Biotalys NV (Euronext Brussel : BTLS) (the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, announces today, in accordance with article 14 of the Act of 2 May 2007 on the discl ...
From Setback To Strength: Forward Air's Bumpy Road To Recovery
Seeking Alpha· 2025-06-14 03:00
Editor's note: Seeking Alpha is proud to welcome Alps Capital as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.I'm a financial analyst with a Master's degree in Corporate and Market Finance. I work on the buy-side, focusing on identifying resilient and undervalued companies across all sectors. While I have a particular interest in the Energy sector due ...
Ethical Web AI Hits Major Milestones in 2025 Growth Strategy
Globenewswire· 2025-06-12 21:19
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Bubblr Inc., operating as Ethical Web AI (OTC: BBLR), a leader in secure, enterprise-grade generative AI, today announced a major achievement in executing its 2025 strategic roadmap. The company has successfully onboarded its first AI Vault SaaS client via the Amazon Web Services (AWS) Marketplace. AI Vault Lands First Client via AWS MarketplaceFollowing its recent debut on the AWS Marketplace, Ethical Web AI’s flagship product, AI Vault, has secured its first ent ...
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
Prnewswire· 2025-06-12 21:17
Protection through 2039, ensuring long-term commercial exclusivity.NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the HT-KIT platform. The patent was officially granted by the Japan Patent Office on May 7, 2025, and exclusive protection is granted until August 27, 2039.The granted patent, titled "Targeting KIT with Splice Sw ...
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
Globenewswire· 2025-06-12 20:30
文章核心观点 美国专利商标局授予AIM ImmunoTech公司一项新专利,该专利涵盖治疗性双链RNA产品制造方法,包括Ampligen,进一步确保公司对该药物合成和使用的控制,为其制造提供专利保护至2041年,有助于公司推进药物项目以获FDA批准 [1][2]。 各部分总结 公司概况 - 公司是一家免疫制药公司,专注于治疗多种癌症、免疫疾病和病毒疾病的疗法研发,主打产品为Ampligen [6]。 专利情况 - 美国专利商标局授予美国专利号12312376,名为“治疗性双链RNA及其生产方法”,专利2041年1月25日到期 [1]。 - 新专利涵盖一系列治疗性双链RNA产品制造方法,包括Ampligen,结合公司其他相关专利,进一步确保公司对该药物合成和使用的控制,为其制造提供专利保护至2041年 [2]。 - 公司整体知识产权组合涵盖Ampligen的制造和使用,其专利还包括用于治疗癌症、新冠后疲劳症状和子宫内膜异位症等 [4]。 专利意义 - 新专利显著延长药物潜在开发周期,为公司争取更多时间安全自信地推进药物项目,以获FDA对Ampligen在一系列适应症上的批准 [3]。 - 该专利是公司加强和巩固围绕Ampligen全球专利组合多年项目的最后一步,公司现对Ampligen的制造、成分及治疗多种未满足医疗需求的应用方式有了更广泛的专利保护 [5]。 孤儿药认定情况 - 公司对Ampligen的知识产权保护还包括来自FDA和EMA的多个孤儿药认定,FDA认定在商业批准后给予7年市场独占权,EMA认定给予10年市场独占权,涉及转移性黑色素瘤、肾细胞癌等多种疾病 [5]。